Platelet Deposition in Renal Transplant Rejection and Treatment with Prostacyclin Infusion
Platelet deposition on vascular endothelium is well known to play a key role in transplant rejection. Colman and co-workers1 and Smith and co-workers2 have described this phenomenon in acute and subacute rejection, whereas Leithner and coworkers3 observed platelet deposition by a radioisotopic method in the majority of patients suffering from chronic rejection too.
KeywordsBlood Urea Nitrogen Acute Rejection Plasma Creatinine Chronic Rejection Transplant Rejection
Unable to display preview. Download preview PDF.
- 2.Smith N, Chandler S, Hawker LM, et al: Indium labelled autologous platelets as diagnostic aid after renal transplantation. Lancet ii: 1241–1242, 1979.Google Scholar
- 3.Leithner C, Sinzinger H, Angelberger P, et al: Indium-111 labelled platelets in chronic kidney transplant rejection. Lancet ií: 213–214, 1980.Google Scholar
- 6.Moncada S, Higgs EA, Vane JR: Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. Lancet i: 18–20, 1977.Google Scholar
- 7.Gerber JG, Nies AS, Friesinger GC, et al: The effect of PGI2 on canine renal function and haemodynamics. Prostaglandins 16: 519–528, 1978.Google Scholar
- 8.Szczeklik A, Nizankowski R, Skawinski S, et al: Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet i:1111–1113, 1979.Google Scholar
- 9.Turney JH, Williams LC, Fewell MR, et al: Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy. Lancet ii: 219–222, 1980.Google Scholar